The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Amyris's revenues will decrease -66.7% and EPS will remain in the red.
The average estimate for revenue is $9.8 million. On the bottom line, the average EPS estimate is -$0.39.
Last quarter, Amyris logged revenue of $5.9 million. GAAP reported sales were 86% lower than the prior-year quarter's $41.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.49. GAAP EPS were -$0.72 for Q4 versus -$1.30 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 7.4%, much better than the prior-year quarter. Operating margin was -598.5%, much worse than the prior-year quarter. Net margin was -742.9%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $93.8 million. The average EPS estimate is -$1.22.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 74 members out of 86 rating the stock outperform, and 12 members rating it underperform. Among 12 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), seven give Amyris a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amyris is hold, with an average price target of $3.50.
Is Amyris the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
- Add Amyris to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Ways to Lose All Your Money in the Stock Market
Avoiding these three fallacies won't guarantee returns, but it'll help you to avoid unnecessary headaches.
Investors Are Betting Big Against Amyris -- Why They're Right
The industrial biotech pioneer is increasingly limited in its financial flexibility. This (probably) won't end well.
Here's Why Amyris Stock Dropped 16.8% in November
The industrial biotech pioneer reported record quarterly revenue, but the devil is in the details.